Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Probability of remission with reinduction with 7+3 versus high-dose cytarabine: analysis of SWOG trial S1203.

Leukemia·2025
Same author

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms.

Leukemia·2023
Same author

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.

Blood cancer journal·2021
Same author

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal.

Blood·2021
Same author

Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021
Same author

Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2021
Same journal

CAR-T cell therapy for multiple myeloma: An update on the current state and future potential.

Best practice & research. Clinical haematology·2025
Same journal

Cancer vaccines in hematologic malignancy: A systematic review of the rational and evidence for clinical use.

Best practice & research. Clinical haematology·2025
Same journal

Immune therapy of haematological cancers.

Best practice & research. Clinical haematology·2025
Same journal

Advances in NK cell therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Adoptive cellular therapies in multiple myeloma.

Best practice & research. Clinical haematology·2025
Same journal

Bispecific T-cell engager therapy for multiple myeloma.

Best practice & research. Clinical haematology·2025
See all related articles

Related Experiment Video

Updated: Jun 18, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

AML in older patients: are we making progress?

Elihu Estey1

  • 1University of Washington School of Medicine, Seattle, WA 9810, USA. eestey@u.washington.edu

Best Practice & Research. Clinical Haematology
|December 5, 2009
PubMed
Summary
This summary is machine-generated.

Survival for older patients has not significantly improved, but progress is being made. New therapies and a better understanding of individual patient factors are enhancing care for elderly individuals.

Related Experiment Videos

Last Updated: Jun 18, 2026

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
11:01

Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease

Published on: August 30, 2011

Area of Science:

  • Geriatric Medicine
  • Hematology
  • Clinical Trials

Background:

  • Older patients (aged 60+) are a heterogeneous group.
  • Age-related outcomes are influenced by performance status, comorbidities, and cytogenetics.
  • Historically, survival improvements for older patients have been limited.

Purpose of the Study:

  • To review recent advancements in the treatment and clinical trial design for older patients.
  • To highlight the evolving understanding of prognostic factors in this demographic.
  • To discuss the shift away from a one-size-fits-all approach to geriatric care.

Main Methods:

  • Review of recent therapeutic developments and clinical trial methodologies.
  • Analysis of prognostic factors impacting older patient outcomes.
  • Examination of changes in clinical practice and patient selection for trials.

Main Results:

  • Introduction of reduced intensity allogeneic hematopoietic stem cell transplant.
  • Refinement of response categories, e.g., complete response with incomplete platelet recovery (CRp).
  • Implementation of selection designs for phase 3 trials and increased awareness of selection bias.

Conclusions:

  • Older patients are not a monolithic group; individual factors are crucial.
  • Therapeutic strategies and trial designs are becoming more personalized.
  • Practices like neutropenic diets and mask recommendations are being re-evaluated.